Impel NeuroPharma Inc logo

Impel NeuroPharma Inc

Impel NeuroPharma, Inc. develops therapies for patients with central nervous system diseases in the United States. The company is developing INP104 (dihydroergotamine mesylate), a drug candidate that is in Phase III clinical study for the treatment of cluster headache; and INP107 (sumatriptan) Nasal Powder, which has completed Phase I testing designed to investigate its safety, tolerability, pharmacokinetics, and delivery. Its product candidates are also developed for the treatment of migraine headache and pain associated with chronic sinusitis. The company was founded in 2015 and is headquartered in Seattle, Washington.

Latest events on Quartr

Previous Events for Impel NeuroPharma Inc




United States of America

About the company

Investor Relations page

Dig deeper into the fundamentals using Quartr - Investor relations

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
Android play link
App store link
Quartr app screenshot